Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970637 | 1.00 | PTGDR2 (0.60) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6970631 | 1.00 | PTGDR2 (0.60) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL13776125 | 0.88 | PTGDR2 (0.77) | PTGDR2MEN1KMT2A | |
| SCHEMBL6975946 | 0.87 | P2RY1 (0.50) | PTGDR2MCL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6978652 | 0.87 | PTGDR2 (0.73) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6975967 | 0.87 | MCL1 (0.54) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6419441 | 0.84 | MCL1 (0.66) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6419439 | 0.84 | MCL1 (0.66) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6419445 | 0.84 | MCL1 (0.66) | PTGDR2MCL1MEN1KMT2A | |
| SCHEMBL6973267 | 0.83 | PDE4A (0.53) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | APP, BDNF, BACE1 | PTGDR2 1502/4885MCL1 1131/4885MEN1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.